Evidence map›Paper›PMID 42584831›Full record

ArticleGeroScience2026

Cognitive components derived from traditional neuropsychological tests and their associations with plasma p-tau217 and p-tau181 in mild cognitive impairment: a multisite analysis.

Ana Perez, Hugo Lewi Hammer, Vebjørn Andersson, Timo Saarinen, Soraya Alfonsín, Guido Maria Giuffrè, Naike Caraglia, Noemi Martellacci, Federico Ramírez-Toraño, Thomas Tveitstøl and 15 more

Abstract read
PubMed Publisher
In one paragraph

Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Ana PerezDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Hugo Lewi HammerOslo Metropolitan University, Oslo, Norway.
Vebjørn AnderssonDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Timo SaarinenBioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland.
Soraya AlfonsínDepartment of Experimental Psychology, Cognitive Psychology and Speech & Language Therapy, Complutense University of Madrid, Madrid, Spain.
Guido Maria GiuffrèMemory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Naike CaragliaMemory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Noemi MartellacciMemory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Federico Ramírez-TorañoDepartment of Experimental Psychology, Cognitive Psychology and Speech & Language Therapy, Complutense University of Madrid, Madrid, Spain.
Thomas TveitstølDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Antti KinnunenBioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland.
Mia LiljeströmBioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland.
Jaakko HottaBioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland.
Anne M KoivistoBioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland.
Davide QuarantaMemory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Clara Quijano-RubioRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Gwendlyn KollmorgenRoche Diagnostics GmbH, Penzberg, Germany.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Erik ChristensenPre Diagnostics AS, Oslo, Norway.
Hanna RenvallBioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland.
Camillo MarraMemory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Fernando MaestúDepartment of Experimental Psychology, Cognitive Psychology and Speech & Language Therapy, Complutense University of Madrid, Madrid, Spain.
Paolo M RossiniDepartment of Neuroscience and Neurorehabilitation, IRCCS San Raffaele, Rome, Italy.
Christoffer Hatlestad-HallDepartment of Neurology, Oslo University Hospital, Oslo, Norway. chrihat@ous-research.no.ORCID http://orcid.org/0000-0002-2501-5378
Ira H HaraldsenDepartment of Neurology, Oslo University Hospital, Oslo, Norway.

Funding

Helse Sør-Øst RHF 2024019Horizon 2020 964220
6 · The paper itself

Abstract

backgroundCurrently, no single biomarker can reliably identify preclinical Alzheimer's disease (AD), particularly at or before the mild cognitive impairment (MCI) stage. Given the heterogeneity of MCI, integrative approaches are needed to improve early risk stratification.

objectives(i) To derive robust latent cognitive components from a multicenter, clinically defined MCI cohort using principal component analysis (PCA); (ii) to investigate the associations between these components and plasma p-tau217 and p-tau181 levels.

methodsData from 742 MCI participants in the AI-Mind cohort were analyzed. Cognitive domains were derived using PCA with varimax rotation and tested for associations with plasma p-tau biomarkers using site-specific linear regressions, adjusted for age, sex, and education.

resultsA reproducible four-component cognitive structure emerged (memory, executive/processing speed, verbal fluency, visuospatial ability), with memory as the most p-tau-sensitive domain. The p-tau217 measure showed stronger associations with memory than p-tau181, though effects varied by site.

conclusionThe findings indicate that a robust four-factor cognitive structure can be identified in clinically defined MCI cohorts without prior biological selection. The association between latent memory factors and plasma p-tau217, observed primarily in cohorts with higher biomarker burden or clearer amnestic profiles, highlights the potential for blood-based biomarkers to refine risk assessment in routine clinical practice.

Indexed as

Alzheimer’s diseaseMild cognitive impairment, p-tau 217Plasma biomarkersp-tau 181, principal component analysis

Identifiers

PMID42584831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.